Teplyakov; Alexey
Patent Applications and Registrations
Patent applications and USPTO patent grants for Teplyakov; Alexey.The latest application filed is for "materials and methods for improved single chain variable fragments".
Company Profile
13.32.41
- Teplyakov; Alexey - Spring House PA
- Teplyakov; Alexey - Phoenixville PA
- Teplyakov; Alexey - Middletown MD
- Teplyakov; Alexey - Radnor PA US
Patent Activity
| Patent | Date |
|---|---|
| Nucleic acids encoding anti-CD154 antibodies Grant 11,421,037 - Fransson , et al. August 23, 2 | 2022-08-23 |
| Anti-CCL17 antibodies Grant 11,414,484 - Boakye , et al. August 16, 2 | 2022-08-16 |
| GM-CSF variants and methods of use Grant 11,208,450 - Rutkoski , et al. December 28, 2 | 2021-12-28 |
| Materials And Methods For Improved Single Chain Variable Fragments App 20210047435 - Luo; Jinquan ; et al. | 2021-02-18 |
| Anti-ccl17 Antibodies App 20210017267 - BOAKYE; Ken ; et al. | 2021-01-21 |
| Prostate specific membrane antigen (PSMA) bispecific binding agents and uses thereof Grant 10,844,122 - Anderson , et al. November 24, 2 | 2020-11-24 |
| Anti-CCL17 antibodies Grant 10,829,549 - Boakye , et al. November 10, 2 | 2020-11-10 |
| Anti-cd154 Antibodies And Methods Of Using Them App 20200317794 - Fransson; Johan ; et al. | 2020-10-08 |
| Human Anti-CD27 Antibodies App 20200277393 - Chen; John ; et al. | 2020-09-03 |
| Methods of inhibiting naive T-cell proliferation using anti-CD27 antibodies Grant 10,689,453 - Chen , et al. | 2020-06-23 |
| Anti-CD154 antibodies and methods of using them Grant 10,669,343 - Fransson , et al. | 2020-06-02 |
| GM-CSF Variants and Methods of Use App 20200148736 - Rutkoski; Thomas ; et al. | 2020-05-14 |
| GM-CSF variants and methods of use Grant 10,562,948 - Rutkoski , et al. Feb | 2020-02-18 |
| Anti-GPRC5D antibodies, bispecific antigen binding molecules that bind GPRC5D and CD3, and uses thereof Grant 10,562,968 - Attar , et al. Feb | 2020-02-18 |
| Agonistic antibodies specifically binding CD40 and methods of use Grant 10,544,229 - Fransson , et al. Ja | 2020-01-28 |
| Methods of Inhibiting Activity Using Anti-CD27 Antibodies App 20190248910 - Chen; John ; et al. | 2019-08-15 |
| Methods of inhibiting T-cell mediated B-cell antibody production using anti-CD27 antibodies Grant 10,301,392 - Chen , et al. | 2019-05-28 |
| Toll-like Receptor 3 Antagonists App 20180179294 - Cunningham; Mark ; et al. | 2018-06-28 |
| Anti-ccl17 Antibodies App 20180171007 - Boakye; Ken ; et al. | 2018-06-21 |
| Anti-CCL17 antibodies Grant 9,944,697 - Boakye , et al. April 17, 2 | 2018-04-17 |
| Methods of reducing clinical symptoms of viral infection by administering a toll-like receptor 3 antagonist Grant 9,932,404 - Cunningham , et al. April 3, 2 | 2018-04-03 |
| Anti- Gprc5d Antibodies, Bispecific Antigen Binding Molecules That Bind Gprc5d And Cd3, And Uses Thereof App 20180037651 - Attar; Ricardo ; et al. | 2018-02-08 |
| CD123 binding agents and uses thereof Grant 9,850,310 - Gaudet , et al. December 26, 2 | 2017-12-26 |
| GM-CSF Variants and Methods of Use App 20170355742 - Rutkoski; Thomas ; et al. | 2017-12-14 |
| Methods of Inhibiting Activity Using Anti-CD27 Antibodies App 20170320957 - Chen; John ; et al. | 2017-11-09 |
| Anti-ror1, Antibodies, Ror1 X Cd3 Bispecific Antibodies, And Methods Of Using The Same App 20170210799 - ANDERSON; Glenn Mark ; et al. | 2017-07-27 |
| Nucleic acid molecules encoding anti-CD27 antibodies Grant 9,683,046 - Chen , et al. June 20, 2 | 2017-06-20 |
| Agonistic Antibodies Specifically Binding CD40 and Methods of Use App 20170088624 - Fransson; Johan ; et al. | 2017-03-30 |
| Toll-Like Receptor 3 Antagonists App 20170058041 - Cunningham; Mark ; et al. | 2017-03-02 |
| Anti-CD154 antibodies and methods of using them App 20170037136 - Fransson; Johan ; et al. | 2017-02-09 |
| Method of treating an inflammatory condition by administering toll-like 3 receptor antagonists Grant 9,522,957 - Cunningham , et al. December 20, 2 | 2016-12-20 |
| Prostate Specific Membrane Antigen (PSMA) Bispecific Binding Agents and Uses Thereof App 20160347840 - Anderson; Glenn ; et al. | 2016-12-01 |
| Toll-like receptor 3 antagonists Grant 9,481,731 - Cunningham , et al. November 1, 2 | 2016-11-01 |
| CD123 Binding Agents and Uses Thereof App 20160068605 - Nemeth; Jennifer F. ; et al. | 2016-03-10 |
| Polynucleotides encoding Toll-Like Receptor 3 antagonists Grant 9,255,153 - Cunningham , et al. February 9, 2 | 2016-02-09 |
| Method of treating asthma or reducing inflammatory cell lung inflammation by administering toll-like receptor 3 antibodies Grant 9,238,693 - Cunningham , et al. January 19, 2 | 2016-01-19 |
| Human Anti-CD27 Antibodies, Methods and Uses App 20150299330 - Chen; John ; et al. | 2015-10-22 |
| Human anti-CD27 antibodies, methods and uses Grant 9,102,737 - Chen , et al. August 11, 2 | 2015-08-11 |
| Anti-CCL17 Antibodies App 20150125458 - Boakye; Ken ; et al. | 2015-05-07 |
| Human tissue factor antibody and uses thereof Grant 8,999,333 - Almagro , et al. April 7, 2 | 2015-04-07 |
| Human tissue factor antibody and uses thereof Grant 8,951,525 - Almagro , et al. February 10, 2 | 2015-02-10 |
| Human Tissue Factor Antibody And Uses Thereof App 20140234304 - ALMAGRO; Juan Carlos ; et al. | 2014-08-21 |
| Toll-Like Receptor 3 Antagonists App 20140212426 - Cunningham; Mark ; et al. | 2014-07-31 |
| Human tissue factor antibody and uses thereof Grant 8,722,044 - Almagro , et al. May 13, 2 | 2014-05-13 |
| Toll-Like 3 Receptor Antagonists App 20140093508 - Cunningham; Mark ; et al. | 2014-04-03 |
| Toll-Like Receptor 3 Antagonists for the Treatment of Metabolic and Cardiovascular Diseases App 20140017250 - Cunningham; Mark ; et al. | 2014-01-16 |
| Toll-Like Receptor 3 Antagonists App 20130280263 - Cunningham; Mark ; et al. | 2013-10-24 |
| Toll-like receptor 3 antagonists Grant 8,540,986 - Cunningham , et al. September 24, 2 | 2013-09-24 |
| Human Anti-cd27 Antibodies, Methods And Uses App 20130243795 - Chen; John ; et al. | 2013-09-19 |
| Toll-Like Receptor 3 Antagonists App 20130244281 - Cunningham; Mark ; et al. | 2013-09-19 |
| Human Tissue Factor Antibody and Uses Thereof App 20130189250 - Almagro; Juan Carlos ; et al. | 2013-07-25 |
| Toll-like receptor 3 antagonists for the treatment of metabolic and cardiovascular diseases Grant 8,460,659 - Cunningham , et al. June 11, 2 | 2013-06-11 |
| Toll-Like Receptor 3 Antagonists for the Treatment of Metabolic and Cardiovascular Diseases App 20130090457 - Cunningham; Mark ; et al. | 2013-04-11 |
| Toll-like receptor 3 antagonists Grant 8,409,567 - Cunningham , et al. April 2, 2 | 2013-04-02 |
| Human Tissue Factor Antibody and Uses Thereof App 20120237528 - Almagro; Juan Carlos ; et al. | 2012-09-20 |
| Toll-like Receptor 3 Antagonists For The Treatment Of Metabolic And Cardiovascular Diseases App 20120064095 - Cunningham; Mark ; et al. | 2012-03-15 |
| Resistin Antagonists And Their Use App 20110071277 - Blake; Simon ; et al. | 2011-03-24 |
| Toll-Like Receptor 3 Antagonists App 20110008352 - Cunningham; Mark ; et al. | 2011-01-13 |
| Toll-Like Receptor 3 Antagonists App 20100166778 - Cunningham; Mark ; et al. | 2010-07-01 |
| Resistin Antagonists And Their Use App 20090162375 - Blake; Simon ; et al. | 2009-06-25 |
| Resistin Antagonists and Their Use App 20090117122 - Carton; Jill ; et al. | 2009-05-07 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 